Welcome to our dedicated page for Neuronetics news (Ticker: STIM), a resource for investors and traders seeking the latest updates and insights on Neuronetics stock.
Neuronetics, Inc. (NASDAQ: STIM) is a commercial stage medical technology and healthcare company focused on neurohealth and psychiatric disorders, and its news flow reflects this focus. The company develops and markets the NeuroStar Advanced Therapy System, a non-drug, noninvasive transcranial magnetic stimulation (TMS) treatment used in office-based settings, and operates Greenbrook TMS treatment centers across the United States. News about Neuronetics often centers on clinical use of NeuroStar TMS, payer coverage decisions, and developments at its Greenbrook clinics.
Investors following STIM news can expect regular updates on quarterly financial and operating results, as the company reports revenue by geography and product category, including NeuroStar system sales, treatment sessions, and U.S. clinic revenue. Press releases also cover changes to its capital structure and credit facilities, such as amendments to its agreement with Perceptive Credit Holdings IV, LP, as well as at-the-market equity offerings and related capital-raising activities.
Company announcements frequently highlight health policy and reimbursement milestones, including expanded coverage for TMS therapy by New York State Medicaid and TRICARE West for specific patient populations with major depressive disorder. Neuronetics also reports on partnerships and agreements that expand access to NeuroStar TMS, such as an exclusive three-year collaboration with Elite DNA Behavioral Health, under which Neuronetics becomes the sole provider of TMS devices across that network and offers operational and patient-support services using the Greenbrook platform.
Additional STIM news items include participation in investor conferences, leadership and executive appointments, inducement equity grants under Nasdaq Listing Rule 5635(c)(4), and publications of real-world clinical data from the NeuroStar outcomes databases. For readers tracking Neuronetics, this news page aggregates these developments so they can monitor financial performance, payer coverage trends, clinical evidence, and corporate actions related to NeuroStar TMS and Greenbrook treatment centers.
Neuronetics, Inc. (Nasdaq: STIM) announced that its 2020 Annual Meeting of Stockholders will be conducted entirely via live webcast on May 26, 2020, at 9:00 am ET, due to the COVID-19 pandemic. Stockholders of record as of April 3, 2020, can participate by logging into the designated website with their control number. Proxy materials distributed earlier will remain valid for voting. The company is committed to ensuring the health and safety of its employees and stakeholders during these challenging times.
Neuronetics, a medical technology company, reported Q1 2020 revenues of $11.5 million, down 10% from $12.7 million in Q1 2019, primarily due to COVID-19 impacts. The U.S. revenue fell 11%, while international revenue increased 64%. The company's active installed base grew 20% year-over-year to 1,119 units. Operating expenses are expected to be reduced to $58-$60 million for 2020 from the previous $76-$78 million guidance following a restructuring. Net loss widened to $12.6 million, or $0.68 per share, compared to a loss of $7.5 million in Q1 2019.